This review highlights biological advances in soft-tissue sarcomas, emphasizing the need to translate emerging genomic, molecular, and immunotherapeutic targets into effective treatments.
Answers are grounded in this paper and cite their sources.
Current evidence insufficient to alter sarcoma care; leaves open translation of genomic and immunotherapeutic targets into effective therapies.
Soft-tissue sarcomas are rare malignant tumors arising from connective tissues and have an overall incidence of about five per 100,000 per year. While this diverse family of malignancies comprises over 100 histological subtypes and many molecular aberrations are prevalent within specific sarcomas, very few are therapeutically targeted. Instead of utilizing molecular signatures, first-line sarcoma treatment options are still limited to traditional surgery and chemotherapy, and many of the latter remain largely ineffective and are plagued by disease resistance. Currently, the mechanism of sarcoma oncogenesis remains largely unknown, thus necessitating a better understanding of pathogenesis. Although substantial progress has not occurred with molecularly targeted therapies over the past 30 years, increased knowledge about sarcoma biology could lead to new and more effective treatment strategies to move the field forward. Here, we discuss biological advances in the core molecular determinants in some of the most common soft-tissue sarcomas - liposarcoma, angiosarcoma, leiomyosarcoma, rhabdomyosarcoma, Ewing's sarcoma, and synovial sarcoma - with an emphasis on emerging genomic and molecular pathway targets and immunotherapeutic treatment strategies to combat this confounding disease.
No takes yet. Share an insight, caveat, or question.
Hoang et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: